Pancreatic Cancer Vaccine Trial Moves Forward After Positive Safety Review

Independent committee recommends ELI-002 7P Phase 2 study continue without changes.

Elicio Therapeutics has announced encouraging news for its pancreatic cancer vaccine, ELI-002 7P. An independent committee (IDMC) reviewed early results from the AMPLIFY-7P Phase 2 study and recommended the trial continue as planned. This means the treatment has shown enough safety and early effectiveness to move forward without changes.

The vaccine is designed for people with pancreatic cancer driven by KRAS mutations, which are common in this disease. Unlike personalized treatments, ELI-002 7P is an “off-the-shelf” vaccine, making it easier and faster to produce. It works by training the immune system to recognize and attack cancer cells after surgery and chemotherapy.

The trial has enrolled 144 patients across 24 U.S. hospitals. Participants either receive the vaccine or standard care, which usually involves regular scans to watch for cancer returning. So far, ELI-002 7P has been well tolerated, and final results on disease-free survival are expected in late 2025.

“Patients with pancreatic cancer urgently need better options,” said Robert Connelly, CEO of Elicio. “We are encouraged by the committee’s recommendation and believe ELI-002 7P has the potential to make a difference.”

If results remain positive, the company plans to meet with the FDA to finalize a Phase 3 study. Elicio is also exploring the vaccine’s use in other cancers linked to KRAS mutations, including colorectal and lung cancer.

Citation: Elicio Therapeutics, “Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer” (August 5, 2025). Read the full press release